Model-Based Evaluation of HangAmDan-B1 and Afatinib Combination Therapy in HCC827 Xenograft Mice with Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Model-Based Evaluation of HangAmDan-B1 and Afatinib Combination Therapy in HCC827 Xenograft Mice with Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

<b>Objectives:</b> HangAmDan-B1 (HAD-B1), a blended herbal mixture, has been investigated as an adjuvant therapy with afatinib (AFT) to treat non-small lung cancer (NSCLC). Although preclinical studies demonstrated promising synergistic results, clinical trials have not yet confirmed the...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sung-yoon Yang, Lien Thi Ngo, Soyoung Lee, Hwi-yeol Yun, Tham Thi Bui, Dong-Hyeon Kim, Jung-woo Chae, Sojung Park
Format:	Article
Language:	English
Published:	MDPI AG 2025-05-01
Series:	Pharmaceuticals
Subjects:	pharmacokinetic/pharmacodynamic modeling afatinib hangamdan-B1 non-small cell lung cancer EGFR-TKI resistance drug–drug interactions
Online Access:	https://www.mdpi.com/1424-8247/18/5/748
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Afatinib amplifies cAMP-induced fluid secretion in a mouse mini-gut model via TMEM16A-mediated fluid secretion and secretory cell differentiation
by: Jutharat Ariyadamrongkwan, et al.
Published: (2025-08-01)

Afatinib Combined with Bevacizumab in the Treatment of Patients with Non-Small Cell Lung Cancer Harboring EGFR G719X, S768I or L861Q/P Mutations
by: Han X, et al.
Published: (2024-11-01)

Case Report: A Bilateral Synchronous Primary Non‐Small Cell Lung Cancer Patient With Two Different EGFR Mutations
by: Thanh‐Dung Quach, et al.
Published: (2025-08-01)

Herb-drug interactions in oncology: pharmacodynamic/pharmacokinetic mechanisms and risk prediction
by: Xiaoyan Duan, et al.
Published: (2025-07-01)

Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions
by: Yang Li, et al.
Published: (2025-04-01)

The RAS‐related GTPase RHOB confers resistance to EGFR‐tyrosine kinase inhibitors in non‐small‐cell lung cancer via an AKT‐dependent mechanism
by: Olivier Calvayrac, et al.
Published: (2016-12-01)

Strategies for the Prevention and Containment of Antibiotic Resistance
by: S.Y. Essack
Published: (2006-02-01)

Molecular mechanism of acquired drug resistance in the EGFR‐TKI resistant cell line HCC827‐TR
by: Tao Yu, et al.
Published: (2020-05-01)

Intracellular cholesterol: new functions and therapeutic approaches in NSCLC EGFR-TKI resistance
by: Linjuan Wang, et al.
Published: (2025-07-01)

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
by: Azhar Ali, et al.
Published: (2018-02-01)

Genetic Risk Factors for Adverse Drug Reactions
by: D. A. Sychev, et al.
Published: (2022-04-01)

Zebrafish xenografts in breast cancer research
by: Xingyan Rong, et al.
Published: (2025-07-01)

Enhancing the Efficacy and Safety of Methotrexate Treatment: A Focus on Drug Interactions (Review)
by: S. A. Doktorova, et al.
Published: (2024-10-01)

The Recovery of Epidermal Proliferation Pattern in Human Skin Xenograft
by: Olga Cherkashina, et al.
Published: (2025-03-01)

High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study
by: Yin Pan, et al.
Published: (2025-11-01)

EGFR‐TKIs Induced DPP4 Drives Metabolic Reprogramming of Persister Cells in Lung Cancer
by: Yuanzhou Zhang, et al.
Published: (2025-08-01)

Multimodal prediction of tyrosine kinase inhibitors therapy outcomes in advanced EGFR-mutated NSCLC patients
by: Xiaodong Chai, et al.
Published: (2025-08-01)

Genomic profiling of a collection of patient-derived xenografts and cell lines identified ixabepilone as an active drug against chemo-resistant osteosarcoma
by: Maria Cristina Manara, et al.
Published: (2025-07-01)

Determining safety of betacarboclomet cream in epidermal delivery to the body of animals
by: G. M. Voytenko, et al.
Published: (2015-08-01)

Pirana and Integrated PMX Tools, a Workbench for NONMEM, NLME, pyDarwin, and RsNLME
by: Rong Chen, et al.
Published: (2025-08-01)

EMP3 is upregulated upon epithelial–mesenchymal transition and contributes to EGFR–tyrosine kinase inhibitor resistance in lung adenocarcinoma
by: Chunyan Wang, et al.
Published: (2025-07-01)

Investigating the Effects of Secondary Metabolites of Streptomyces Calvus Bacteria on Human Liver Cancer Cells (HCC)
by: Haleh Halali, et al.
Published: (2025-08-01)

COMPARISON OF PHARMACOKINETICS AND PHARMACODYNAMICS OF THE ORIGINAL AND GENERIC ENALAPRIL IN THE ELDERLY PATIENTS WITH ARTERIAL HYPERTENSION
by: O. P. Bobrova, et al.
Published: (2015-12-01)

Pharmacodynamics, pharmacokinetics, interactions with other drugs, toxicity and clinical effectiveness of proton pump inhibitors
by: Łukasz Wołowiec, et al.
Published: (2025-07-01)

EXPERT EVALUATION OF PRECLINICAL STUDIES OF PRIMARY AND SECONDARY PHARMACODYNAMICS OF MEDICINES
by: G. N. Engalycheva, et al.
Published: (2018-12-01)

Model‐Informed Optimal Dosing of Anti‐CD47 Antibody Using Target‐Mediated Drug Disposition Model
by: Seongmee Jeong, et al.
Published: (2025-08-01)

Optimizing phage therapy for Salmonella Pullorum: dosage, timing, and pharmacokinetics define treatment efficacy in SPF chickens
by: Lulu Li, et al.
Published: (2025-11-01)

Sex differences in the pharmacotherapy of neurological patients
by: Lejla Ćorić, et al.
Published: (2025-06-01)

Population Pharmacokinetic/Pharmacodynamic and Exposure–Response Modeling of Garadacimab in Healthy Volunteers and Patients With Hereditary Angioedema
by: Ramon Garcia, et al.
Published: (2025-05-01)

Preparation and Evaluation of Tadalafil-Loaded Nanoemulgel for Transdermal Delivery in Cold-Induced Vasoconstriction: A Potential Therapy for Raynaud’s Phenomenon
by: Shery Jacob, et al.
Published: (2025-05-01)

Fasting-mimicking diet enhances EGFR-TKI efficacy in oral cancer through dual mechanisms: direct cancer cell sensitization and tumor-associated macrophage crosstalk
by: Lei Wang, et al.
Published: (2025-07-01)

Pharmacological properties and therapeutic potential of berberine: a comprehensive review
by: Ke-Qin Fan, et al.
Published: (2025-08-01)

The safety, tolerability, pharmacokinetics, and pharmacodynamics of nebulized pegylated interferon α-2b in healthy adults: a randomized phase 1 trial
by: Wenqi Huang, et al.
Published: (2025-05-01)

A randomized trial to evaluate the pharmacokinetics, pharmacodynamics, and safety of vadadustat in patients with anemia associated with chronic kidney disease receiving hemodialysis
by: Pamela Navarro-Gonzales, et al.
Published: (2025-08-01)

The Prevalence of Potential Drug-Drug-Gene Interactions: A Descriptive Study Using Swiss Claims Data
by: Wittwer NL, et al.
Published: (2025-08-01)

Population Pharmacokinetic/Pharmacodynamic Study of Linezolid in Hospital-Acquired Pneumonia Patients with Renal Insufficiency
by: Xu J, et al.
Published: (2024-11-01)

Antimalarial Combination Therapies Increase Gastric Ulcers Through an Imbalance of Basic Antioxidative‑Oxidative Enzymes in Male Wistar Rats.
by: Kalange, Muhamudu, et al.
Published: (2023)

From a traditional medicine monomer to a modern neurotherapeutic scaffold: a review of SAR-Driven tetramethylpyrazine derivatives for cerebrovascular and cognitive health
by: Xiaodi Wang, et al.
Published: (2025-08-01)

Results of the Estimation of Biosimilarity of RinLiz<sup>®</sup> (LLC «GEROPHARM», Russia) and Humalog<sup>®</sup> (Lilly France, France) Using the Method of the Hyperinsulinemic Eulygemic Clamp on Healthy Voluntary
by: A. Yu. Mayorov, et al.
Published: (2020-05-01)

Cannabidiol as an immune modulator: A comprehensive review
by: Khizra Mujahid, et al.
Published: (2025-05-01)